You can call it whatever you want, but it was granted based on Pediatric safety study that was done per Pediatric Written Request from FDA. Whatever you want to call it, it expires in August 2018.
I've explained this several times already. There is a specific provision of Hatch-Waxman that disallows Pediatric Exclusivity to be applied against an applicant who has a successful court decision in a Paragraph IV challenge. This is how Xtampza was approved exactly one week afer expiration of OxyContin's nasal abuse exclusivity. The Pediatric Exclusivity does not apply to Xtampza because they won in court, and that is law. Look it up.
Okay, then, what exactly do you think the NPP exclusivity through August 13, 2018 means? You said yourself you could not figure out why Rexista did not get Priority Review when all other ADF's did. I told you last week they did not have Priority Review and would not get it and why. Now here we are a week later, still without Priority Review, still with you telling me how wrong I am, and still with you trying to figure out why they didn't get Priority Review. Let me know when you figure it out.